AARON ROYSTON

Aaron Royston stands as a distinguished Managing Partner at venBio, a leading venture capital firm dedicated to advancing the life sciences sector. At venBio, Mr. Royston is instrumental in shaping the firm's investment strategy, focusing on companies that are at the forefront of developing innovative therapeutics. His expertise lies in identifying promising biotechnology ventures with the potential to address significant unmet medical needs and transform patient outcomes.

Mr. Royston's investment focus areas are deeply rooted in the biotechnology and pharmaceutical industries. He targets companies engaged in novel drug discovery and development across various therapeutic areas, including immunology, oncology, rare diseases, and neuroscience. His approach involves a rigorous evaluation of scientific merit, clinical potential, and market opportunity, ensuring venBio supports companies with robust pipelines and strong leadership teams. He is known for his strategic insights and ability to guide portfolio companies through critical development milestones, from preclinical stages to clinical trials and commercialization.

Before joining venBio in 2013, Aaron Royston built a formidable career marked by significant contributions across the biotech landscape. He previously served as a Partner at Third Rock Ventures, a renowned life sciences venture capital firm, where he was involved in company creation and investment. Prior to that, he held the position of Vice President of Business Development at Portola Pharmaceuticals, a biopharmaceutical company focused on thrombosis and other hematologic disorders. His foundational experience was honed at Genentech, a pioneering biotechnology company, where he held various roles spanning product development, commercial strategy, and business development. This diverse background provides him with a comprehensive understanding of the entire drug development lifecycle, from scientific inception to market entry.

Throughout his tenure at venBio, Aaron Royston has been a key driver behind several successful investments. He has served on the boards of numerous innovative companies, including Apellis Pharmaceuticals, a company focused on complement-mediated diseases, and Harmony Biosciences, which develops therapies for patients with rare neurological disorders. Other notable board directorships include Aulos Bioscience, Aerovate Therapeutics, Allakos, Kyverna Therapeutics, RAPT Therapeutics, and Tizona Therapeutics, among others. These roles underscore his commitment to fostering the growth of companies that are developing transformative medicines. Mr. Royston earned his Ph.D. in Chemistry from the University of California, Berkeley, and a B.A. in Chemistry from Dartmouth College, providing him with a strong scientific foundation that underpins his investment acumen. His leadership and deep industry knowledge continue to position venBio at the forefront of life sciences venture capital.